LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
411
via finance.yahoo.comBusiness & Companies

Amgen advances MariTide obesity drug into Phase 3 trials

FROM THE WIRE · FINANCE.YAHOO.COM

Amgen (NasdaqGS:AMGN) has advanced its obesity drug candidate MariTide into Phase 3 clinical trials, targeting the growing anti-obesity treatment market. The firm is positioning MariTide to compete with existing anti-obesity therapies from established players such as Eli Lilly…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralProgress of an anti-obesity drug can shift expectations in the obesity therapy market where Lilly and Novo Nordisk compete.AI-generated summary
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.